โ Scribed by Giovanni Appendino; Gian Cesare Tron; Giancarlo Cravotto; Giovanni Palmisano; Rita Annunziata; Germano Baj; Nicola Surico
No coin nor oath required. For personal study only.
Synthetic protocols for the manipulation of the modifications. These data suggest that chemical manipulation can effectively dissect cytotoxicity and tumour-polyhydroxylated southern region of ingenol (1a) were developed, and a series of isosteres of the anticancer promoting activity (or potential) of ingenoids, affording more optimal candidates for development, like 20-deoxy-20-compound ingenol 3,20-dibenzoate (1b) was prepared. The biological evaluation of these compounds showed that fluoroingenol 3,20-dibenzoate (5b). In mild acidic medium, an unexpected vinylogous retro-pinacol rearrangement of cytotoxicity was relatively tolerant to changes at C-20, while PKC activation was markedly affected by these ingenol to a tigliane derivative was observed.
Ingenol (1a) is a diterpenoid polyol first characterised in evaluation of the antitumour activity. The potential of ingenol as a scaffold for bioactivity was further fuelled by the the course of studies aimed at the identification of the irritant and co-cancerogenic constituents of plants from the discovery of the outstanding anti-HIV activity of some of its derivatives, which are able to downregulate CD4 ex-spurge family (Euphorbiaceae). [1] Paradoxically, following a seminal report by Kupchan on the anticancer activity of pression in host cells. [11] As with cytotoxicity, the anti-HIV activity was not seemingly directly correlated to PKC acti-ingenol-3,20-dibenzoate (1b), [2] various derivatives of ingenol were also identified as the active constituents of anti-vation. [11] tumour plant extracts, [3] and certain ingenol mono-and diesters were even reported as powerful inhibitors of the enzyme protein kinase C (PKC), [4] the target of tumor-promoting phorboid esters. [5] Dual co-cancerogenic and antitumour activity is not unprecedented for PKC activators, [6] but, at least for ingenol esters, a limited overlapping seems to exist between these contrasting actions, since many cytotoxic ingenol esters lack a free hydroxyl at C-20. This group is required for binding of phorboids to PKC by a twofold hydrogen bonding interaction, where the 20hydroxyl acts both as a donor and as an acceptor. [7] Esterification of the 20-hydroxyl has been suggested to abolish PKC activation while keeping the anticancer activity, [3] but the matter is complicated by the possibility of enzymatic hydrolysis of the 20-ester group, as in the case of ingenol
The structural complexity and the spectacular biological 3,20-dibenzoate itself (1b). This compound shows a low afactivity of ingenol derivatives has sparked great interest, finity for PKC, [8] but was found to be very active in in vivo and generated an intense synthetic activity. [12] However, irritancy and tumour-promotion assays, [9] presumably besystematic investigations on the structure-activity relationcause of the enzymatic loss of the 20-ester group and the ships and information on the cellular targets underlying the formation the corresponding 3-monoester (1c), a powerful cytotoxic and anti-HIV properties of these compounds are PKC activator. [8] Since certain ingenol-3-monoesters are still lacking. Furthermore, interference in the biological cytotoxic, [10] the hydrolysis at C-20 might also affect the measurements by PKC activation from 20-deacylderivatives [a] Dipartimento di Scienza e Tecnologia del Farmaco, formed in the assay conditions remains an open issue,
๐ SIMILAR VOLUMES
A simple synthesis of sugar fatty acid esters was developed in a nonaqueous solution using lipase modified by synthetic detergent. Esterification of sugar was accelerated by continuous removal of water from the reaction mixture with a molecular sieve. When glucose and palmitic acid (1:1 by mole) wer